Ramón Rami-Porta MD , Katherine K. Nishimura PhD, MPH , Dorothy J. Giroux MS , Frank Detterbeck MD , Giuseppe Cardillo FRCS, FETCS , John G. Edwards PhD, FRCS(C/Th) , Kwun M. Fong MD, M.B.B.S., FRACP , Meredith Giuliani M.B.B.S. , James Huang MD , Kemp H. Kernstine Sr. MD, PhD , Edith M. Marom MD , Andrew G. Nicholson DM, FRCPath. , Paul E. Van Schil MD , William D. Travis MD , Ming S. Tsao MD , Shun-Ichi Watanabe MD , Valerie W. Rusch MD , Hisao Asamura MD , Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards, and Participating Institutions
{"title":"IASLC 肺癌分期项目:关于修订即将出版的(第九版)《肺癌 TNM 分期》中 TNM 分期组别的建议。","authors":"Ramón Rami-Porta MD , Katherine K. Nishimura PhD, MPH , Dorothy J. Giroux MS , Frank Detterbeck MD , Giuseppe Cardillo FRCS, FETCS , John G. Edwards PhD, FRCS(C/Th) , Kwun M. Fong MD, M.B.B.S., FRACP , Meredith Giuliani M.B.B.S. , James Huang MD , Kemp H. Kernstine Sr. MD, PhD , Edith M. Marom MD , Andrew G. Nicholson DM, FRCPath. , Paul E. Van Schil MD , William D. Travis MD , Ming S. Tsao MD , Shun-Ichi Watanabe MD , Valerie W. Rusch MD , Hisao Asamura MD , Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards, and Participating Institutions","doi":"10.1016/j.jtho.2024.02.011","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The TNM classification of lung cancer is periodically revised. The International Association for the Study of Lung Cancer collected and analyzed a new database to inform the forthcoming ninth edition of the TNM classification. The results are herewith presented.</p></div><div><h3>Methods</h3><p>After exclusions, 76,518 patients from a total of 124,581 registered patients were available for analyses: 58,193 with clinical stage, 39,192 with pathologic stage, and 62,611 with best stage NSCLC. The proposed new N2 subcategories (N2a, involvement of single ipsilateral mediastinal or subcarinal nodal station, and N2b, involvement of multiple ipsilateral mediastinal nodal stations with or without involvement of the subcarinal nodal station) and the new M1c subcategories (M1c1, multiple extrathoracic metastases in one organ system, and M1c2, multiple extrathoracic metastases in multiple organ systems) were considered in the survival analyses. Several potential stage groupings were evaluated, using multiple analyses, including recursive partitioning, assessment of homogeneity within and discrimination between potential groups, clinical and statistical significance of survival differences, multivariable regression, and broad assessment of generalizability.</p></div><div><h3>Results</h3><p>T1N1, T1N2a, and T3N2a subgroups are assigned to IIA, IIB, and IIIA stage groups, respectively. T2aN2b and T2bN2b subgroups are assigned to IIIB. M1c1 and M1c2 remain in stage group IVB. Analyses reveal consistent ordering, discrimination of prognosis, and broad generalizability of the proposed ninth edition stage classification of lung cancer.</p></div><div><h3>Conclusions</h3><p>The proposed stages for the ninth edition TNM improve the granularity of nomenclature about anatomic extent that has benefits as treatment approaches become increasingly differentiated and complex.</p></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer\",\"authors\":\"Ramón Rami-Porta MD , Katherine K. Nishimura PhD, MPH , Dorothy J. Giroux MS , Frank Detterbeck MD , Giuseppe Cardillo FRCS, FETCS , John G. Edwards PhD, FRCS(C/Th) , Kwun M. Fong MD, M.B.B.S., FRACP , Meredith Giuliani M.B.B.S. , James Huang MD , Kemp H. Kernstine Sr. MD, PhD , Edith M. Marom MD , Andrew G. Nicholson DM, FRCPath. , Paul E. Van Schil MD , William D. Travis MD , Ming S. Tsao MD , Shun-Ichi Watanabe MD , Valerie W. Rusch MD , Hisao Asamura MD , Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards, and Participating Institutions\",\"doi\":\"10.1016/j.jtho.2024.02.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>The TNM classification of lung cancer is periodically revised. The International Association for the Study of Lung Cancer collected and analyzed a new database to inform the forthcoming ninth edition of the TNM classification. The results are herewith presented.</p></div><div><h3>Methods</h3><p>After exclusions, 76,518 patients from a total of 124,581 registered patients were available for analyses: 58,193 with clinical stage, 39,192 with pathologic stage, and 62,611 with best stage NSCLC. The proposed new N2 subcategories (N2a, involvement of single ipsilateral mediastinal or subcarinal nodal station, and N2b, involvement of multiple ipsilateral mediastinal nodal stations with or without involvement of the subcarinal nodal station) and the new M1c subcategories (M1c1, multiple extrathoracic metastases in one organ system, and M1c2, multiple extrathoracic metastases in multiple organ systems) were considered in the survival analyses. Several potential stage groupings were evaluated, using multiple analyses, including recursive partitioning, assessment of homogeneity within and discrimination between potential groups, clinical and statistical significance of survival differences, multivariable regression, and broad assessment of generalizability.</p></div><div><h3>Results</h3><p>T1N1, T1N2a, and T3N2a subgroups are assigned to IIA, IIB, and IIIA stage groups, respectively. T2aN2b and T2bN2b subgroups are assigned to IIIB. M1c1 and M1c2 remain in stage group IVB. Analyses reveal consistent ordering, discrimination of prognosis, and broad generalizability of the proposed ninth edition stage classification of lung cancer.</p></div><div><h3>Conclusions</h3><p>The proposed stages for the ninth edition TNM improve the granularity of nomenclature about anatomic extent that has benefits as treatment approaches become increasingly differentiated and complex.</p></div>\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1556086424000790\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1556086424000790","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
导言:肺癌的肿瘤、结节和转移(TNM)分类定期进行修订。国际肺癌研究协会(International Association for the Study of Lung Cancer)收集并分析了一个新的数据库,为即将发布的第 9 版 TNM 分类提供信息。现将结果公布于众:方法:从 124,581 名登记患者中剔除了 76,518 名患者后,对其进行了分析:58,193例为临床分期,39,192例为病理分期,62,611例为最佳分期非小细胞肺癌。生存分析中考虑了新提出的 N2 亚类(N2a,单个同侧纵隔或心包下结节站受累;N2b,多个同侧纵隔/心包下结节站受累)和新提出的 M1c 亚类(M1c1,一个器官系统中的多个胸外转移;M1c2,多个器官系统中的多个胸外转移)。采用多种分析方法对几种可能的分期分组进行了评估,包括递归分区、评估可能分组内的同质性和分组间的区分度、生存差异的临床和统计学意义、多变量回归和广泛的可推广性评估:结果:T1N1、T1N2a 和 T3N2a 亚组分别归入 IIA、IIB 和 IIIA 分期组。T2aN2b 和 T2bN2b 亚组被归入 IIIB 期。M1c1 和 M1c2 仍属于 IVB 阶段组。分析表明,第 9 版肺癌分期分类法具有一致的排序、预后判别能力和广泛的普适性:结论:第 9 版 TNM 的拟议分期提高了解剖学范围命名的精细度,随着治疗方法的日益分化和复杂化,这种分期将带来更多益处。
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer
Introduction
The TNM classification of lung cancer is periodically revised. The International Association for the Study of Lung Cancer collected and analyzed a new database to inform the forthcoming ninth edition of the TNM classification. The results are herewith presented.
Methods
After exclusions, 76,518 patients from a total of 124,581 registered patients were available for analyses: 58,193 with clinical stage, 39,192 with pathologic stage, and 62,611 with best stage NSCLC. The proposed new N2 subcategories (N2a, involvement of single ipsilateral mediastinal or subcarinal nodal station, and N2b, involvement of multiple ipsilateral mediastinal nodal stations with or without involvement of the subcarinal nodal station) and the new M1c subcategories (M1c1, multiple extrathoracic metastases in one organ system, and M1c2, multiple extrathoracic metastases in multiple organ systems) were considered in the survival analyses. Several potential stage groupings were evaluated, using multiple analyses, including recursive partitioning, assessment of homogeneity within and discrimination between potential groups, clinical and statistical significance of survival differences, multivariable regression, and broad assessment of generalizability.
Results
T1N1, T1N2a, and T3N2a subgroups are assigned to IIA, IIB, and IIIA stage groups, respectively. T2aN2b and T2bN2b subgroups are assigned to IIIB. M1c1 and M1c2 remain in stage group IVB. Analyses reveal consistent ordering, discrimination of prognosis, and broad generalizability of the proposed ninth edition stage classification of lung cancer.
Conclusions
The proposed stages for the ninth edition TNM improve the granularity of nomenclature about anatomic extent that has benefits as treatment approaches become increasingly differentiated and complex.
期刊介绍:
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.